Whether providing seed funding to startups, growth capital to early-stage companies, or financing buyouts, venture capital funding plays a critical role in sustaining the life sciences ecosystem.
Our global team of venture capital lawyers advise venture capital funds, life sciences companies with a captive venture fund, as well as universities and other academic research institutions. We provide multidisciplinary advice throughout the "venture capital lifecycle from company formation through fundraising and investments to eventual exit.
Regulation is simply a reality of doing business in this industry. Our venture capital lawyers regularly access our world-renowned global regulatory team to perform due diligence investigations of regulatory issues and risk factors, including the relevant approval pathway and reimbursement strategy for your product. We also serve as special regulatory counsel to issuers and underwriters in conjunction with initial public offerings and follow-on offerings.
Many of our team members have in-depth experience in industry and government, including at the FDA and other key regulatory agencies, and hold advance degrees in relevant disciplines.
Novartis Institutes for Biomedical Research on a number of venture capital transactions.
OncoVerity, a pioneer in applying advanced bioinformatics to drug development, on the closing of a Series A extension financing led by existing investors, argenx and RefinedScience.
Eurazeo, Bpifrance and Accel on their Series G investment in Doctolib, which, with its €5.8bn valuation, became the most valuable unicorn in the French tech sector at the time of closing.
Rice University on its launch of RBL LLC, a biotech venture creation studio developed out of the Rice Biotech Launch Pad, the university’s biotech innovation accelerator.
CatalYm GmbH, a Munich-based life sciences company, on a significant US$150m venture capital funding round.
